TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03799458

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active High-definition transcranial direct current stimulation (HD-tDCS)
Description: Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates.
Study: NCT03073291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsible Marijuana Vendor Training
Description: Employees at retail recreational marijuana stores assigned to the the responsible marijuana vendor training will register them on TrainToTend online training program, create a user profile, and complete the training within four weeks from initial registration. Personnel who complete the training will receive a certificate of completion. New hires at the stores during the trial will be registered and complete the training within four weeks of commencing work. Separate versions of the training will be available reflecting differences in the laws/regulations on recreational marijuana sales in Colorado, Oregon, and Washington State and the content will be reviewed and approved by state regulators.
Study: NCT01394120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Therapy Tailored Treatment
Description: Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen~* Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX~* TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX~* TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI~* TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine~* TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent~* TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib
Study: NCT03799458

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High-definition transcranial direct current stimulation (HD-tDCS)
Description: Sham HD-tDCS delivers sham current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates
Study: NCT01394120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy
Description: Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
Study: NCT04607772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose: 375 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose: 375 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose: 375 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose: 375 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose: 375 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose: 375 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Dose: 90 mg/m\^2
Study: NCT04299711

Intervention type: OTHER
Intervention: Exposed to the novel coronavirus disease 2019
Description: Exposed to the novel coronavirus disease 2019

Intervention type: OTHER
Intervention: Exposed to the novel coronavirus disease 2019
Description: Exposed to the novel coronavirus disease 2019

Intervention type: OTHER
Intervention: Exposed to the novel coronavirus disease 2019
Description: Exposed to the novel coronavirus disease 2019

Intervention type: OTHER
Intervention: Exposed to the novel coronavirus disease 2019
Description: Exposed to the novel coronavirus disease 2019
Study: NCT04165291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: F4C
Description: Fathers for Change (F4C) focuses on: 1) the fathering role to facilitate engagement, 2) RF to understand self, partner and children and emotion regulation skills to reduce IPV and child maltreatment. F4C focuses on understanding of emotional experiences, how they impact thinking and behaviors related to partners, co-parents and children. F4C clients will meet individually with their F4C therapist for 50 minutes per week over 16 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BIP
Description: The Batterer Intervention Program (BIP) is a psychoeducational intervention that will be delivered in 50- minute individual weekly sessions over 16 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including role plays to teach anger management skills.
Study: NCT03174340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Once per week, participants will be enrolled in supervised group exercise intervention. They will be encouraged in walking 45 minutes per day
Study: NCT02630771

Intervention type: PROCEDURE
Intervention: Pressure pain threshold
Description: Pressure algometry over thenar eminence, bilateral masseter muscles measured at baseline and during conditioned pain modulation

Intervention type: PROCEDURE
Intervention: Pressure pain threshold
Description: Pressure algometry over thenar eminence, bilateral masseter muscles measured at baseline and during conditioned pain modulation

Intervention type: PROCEDURE
Intervention: Pressure pain threshold
Description: Pressure algometry over thenar eminence, bilateral masseter muscles measured at baseline and during conditioned pain modulation
Study: NCT02351752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR\>60)
Study: NCT01350206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic resection
Description: HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
Study: NCT04603859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective induction of labor at 39 gestational weeks and 0 to 3 days
Description: Elective induction of labor (eIOL) according to local policies
Study: NCT01642394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Program
Description: The intervention will be performed by patients with type 2 diabetes and health professionals and it will be divided in 6 group sessions for two and a half hours each, on a weekly basis for 6 weeks. The session content includes techniques for dealing with problems in general, promotion of exercise, nutrition concepts, proper use of medication, effective communication and basic knowledge about diabetes and its complications. The sessions are supported with educational material.~Two leaders, previously trained in the DSMP, will lead each group. The leading status (patient or health care professional) is obtained after attending a 6-week structured program of training, a successful completion of 4 days of training sessions, and taking part in a full course for patients with a proven leader.
Study: NCT01190540

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training and supervision
Description: On-Site-Support (OSS) service training will occur monthly for a period of 9 months. This training and supervision will support the proper utilization of newly learned clinical skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training and Supervision
Description: On-Site-Support (OSS) service training will occur monthly for a period of 9 to 15 months. This training and supervision will support the proper utilization of newly learned clinical skills and continuous quality improvement of processes of care. For the control group, the OSS training will occur during phase 2, after a randomly assigned wait list control period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Management of Infectious Disease (IMID)
Description: The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Management of Infectious Disease (IMID)
Description: The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
Study: NCT02275286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Escalating or deescalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks.~Cohort A: unlimited cycles. Cohort B: 3 cycles. Cohort C: 3 cycles. Cohort D: cycles of trabectedin will be provided and patients will subsequently be evaluated for surgery.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction). Cohort B: 45Gy in 25 fractions (1.8Gy/fraction). Cohort C: 45Gy in 25 fractions (1.8Gy/fraction). Cohort D: 45Gy in 25 fractions (1.8Gy/fraction).
Study: NCT04358484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years - ASD and Language Delay®
Description: The IY - ASLD Program will consist of 22 weekly online group sessions for parents of children between 2-5 years of age with symptoms or a diagnosis of ASD or delayed language acquisition. The program will be conducted by a therapist and a co-therapist, trained in the model.~Fidelity to the intervention will be assessed in accordance with the regulations of the program. All of the therapists and co-therapists will be trained in the intervention by accredited trainers. The three main therapists will be supervised by accredited supervisors of the IY Program, seeking accreditation in the intervention. As the intervention IY - ASLD has not been translated into Spanish, the English materials will be used with simultaneous translation into Spanish language.
Study: NCT03802097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No use of antimicrobial prophylaxis
Description: Do not use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of antimicrobial prophylaxis
Description: Use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
Study: NCT01698697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
Study: NCT03732248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Immunosuppressive drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert drug
Study: NCT03120650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture
Description: Acupoint selection: Shenting (DU24; Baihui (DU20; and upper 1/5 and middle 2/5 in the contralateral motor area (upper: 0.5 cm posterior to the midpoint of the front and rear midline; middle 2/5: intersection between the eyebrow line and the leading edge of the temple hairline.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Rehabilitation plans will be made according to the Guidelines for Stroke Rehabilitation in China (Cerebrovascular Disease Association and the Neurological Rehabilitation Association of Neurology Branch of the Chinese Medical Association, 2012), including physical therapy and occupational therapy.
Study: NCT00079105

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bleomycin sulfate
Description: Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone hydrochloride
Description: Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: procarbazine hydrochloride
Description: Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine sulfate
Description: Treatment
Study: NCT03835858

Intervention type: OTHER
Group type: OTHER
Intervention: Respiratory physiotherapy
Description: The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
Study: NCT03626129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oximetry guided deflation
Description: At the cath.lab. (Step 1) a hemostasis test is performed: oxymetry device on the thumb, compress a.ulnaris, evaluate if curve on device (=Patent hemostasis). If patent no further action. If not patent, air is deflated until a.radialis is patent (curve on device and no bleeding). If bleeding occurs before patency then re-inflate 1-2 ml. air until hemostasis (=no patent hemostasis). In patients with Patent hemostasis no action is taken in sixty minutes whereafter the TR-band is fully deflated (Step 2), and if bleeding then air is re-inflated until hemostasis and step 2 is repeated every 20 minutes until the TR-band is fully deflated with hemostasis. If no patent hemostasis at cath.lab. a hemostasis test is performed after 20 min. If patent hemostasis is achieved no action is taken in sixy minutes (as above). If still not patent then further action as in group A.
Study: NCT02443038

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: 16 bi-weekly 50-60 minute yoga classes, followed by daily, 10 minute home exercise poses and 5 minute relaxation, the control group will practice 5 minutes relaxation, each day between classes.~The first of 3 classes is the 8-10 member advisory board, the second and third classes with 10-15 participants in each workshop will be held in other counties. There will be 2-3 months between the first set of classes and second and third set of classes to refine methods and conduct enrollment and testing for the subsequent groups.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yoga
Description: 16 bi-weekly 50-60 minute yoga classes, followed by daily, 10 minute home exercise poses and 5 minute relaxation, the control group will practice 5 minutes relaxation, each day between classes.~The first of 3 classes is the 8-10 member advisory board, the second and third classes with 10-15 participants in each workshop will be held in other counties. There will be 2-3 months between the first set of classes and second and third set of classes to refine methods and conduct enrollment and testing for the subsequent groups.
Study: NCT03840785

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Argentine tango
Description: Argentine tango sessions will consist of:~* Body perception and body control: sitting, standing then moving around four axes : space, time, energy, gravity.~* Awareness of oneself, of other and music: listening, communication, touch, empathy, kinesthesia, letting go, feeling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Argentine tango
Description: Argentine tango sessions will consist of:~* Body perception and body control: sitting, standing then moving around four axes : space, time, energy, gravity.~* Awareness of oneself, of other and music: listening, communication, touch, empathy, kinesthesia, letting go, feeling
Study: NCT01275924

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tightrope Syndesmosis Repair Kit
Description: Tightrope Syndesmosis Repair Kit

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Syndesmotic screw
Description: Quadricortical syndesmotic screw
Study: NCT01921972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine CR
Description: 24 mg/day with dose-titration over twelve weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine CR
Description: 24 mg/day with dose-titration over twelve weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: memantine 10 mg b.i.d. with a dose titration of sixteen weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be similar in appearance to Memantine
Study: NCT04607772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Dose: 90 mg/m\^2
Study: NCT01298297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: 0.4 mg, SL (sublingual) Buprenorphine PLUS 5 ml Placebo IV (in the vein)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Placebo SL PLUS 5 ml Morphine sulfate (1mg/ml) IV
Study: NCT01410110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training + Work Therapy
Description: Cognitive training for 5 hours per week for 13 weeks and 15 hours of work therapy
Study: NCT04607772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Dose: 1.8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Dose: 1.8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Dose: 420, 560 mg
Study: NCT01410110

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Work Therapy
Description: 20 hours per week of work therapy
Study: NCT04607772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose: 20, 25 mg
Study: NCT01897311

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation
Study: NCT02071576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proscan
Description: One device (500 Hz Excimer Laser - TENEO) with one intervention (Proscan)
Study: NCT00826085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox in combination with Microwave Hyperthermia (heat)
Description: ThermoDox is a 30 minute intravenous infusion followed by hyperthermia within 60 minutes of infusion completion.~Hyperthermia is a therapy used to heat tumors for 60 minutes. Using heat energy, the tumor is heated to a certain temperature. The heat can damage cancer cells at levels that are usually safe for normal cells and can be used to attack cancer in four major ways: 1) heat damages or weakens the cells of the tumor; 2) heat increase blood flow through the weakened tumor; 3) increased blood flow raises oxygen levels in tumors; and 4) when the body senses fever it can stimulate the nature immune system.~All patients will receive up to six ThermoDox/hyperthermia treatments at 21-day intervals.
Study: NCT00539526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Description: bimatoprost 0.03%, 1 drop nightly for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost 0.004%
Description: travoprost 0.004% eye drops, 1 drop nightly for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% eye drops
Description: latanoprost 0.005%, 1 drop nightly for 3 months
Study: NCT03789526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guidance
Description: ultrasound guidance of tendon injection
Study: NCT03060824

Intervention type: OTHER
Intervention: Blood sampling
Description: To explore changes in osmolality during coronary artery bypass grafting surgery with the aid of Cardiopulmonary Bypass by repeated measurements of osmolality and concentration shifts of sodium, glucose and urea in plasma.